...
首页> 外文期刊>Trials >Inverted internal limiting membrane insertion combined with air tamponade in the treatment of macular hole retinal detachment in high myopia: study protocol for a randomized controlled clinical trial
【24h】

Inverted internal limiting membrane insertion combined with air tamponade in the treatment of macular hole retinal detachment in high myopia: study protocol for a randomized controlled clinical trial

机译:内限膜倒置联合空气填塞治疗高度近视黄斑裂孔性视网膜脱离:一项随机对照临床研究的研究方案

获取原文
           

摘要

Macular hole retinal detachment (MHRD) occurs most commonly in high myopia and causes severe visual impairment and greatly reduces the quality of life. The aim of this study is to evaluate the efficacy and safety of inverted internal limiting membrane insertion combined with air tamponade in the treatment of MHRD in high myopia, and also to compare the treatment efficacy with that of the conventional “vitrectomy plus internal limiting membrane peeling plus silicone oil tamponade” method for high myopia-associated MHRD. In this clinical trial, 38 patients with MHRD in high myopia will be randomly assigned to two groups (Group 1: standard 3-port 23-gauge pars plana vitrectomy plus internal limiting membrane peeling plus air-fluid exchange plus silicone oil infusion; Group 2: standard 3-port 23-gauge pars plana vitrectomy plus internal limiting membrane peeling plus inverted internal limiting membrane insertion plus air-fluid exchange). The primary outcome is macular hole closure rate in 3?months after the initial surgery. The secondary outcomes are best corrected visual acuity (BCVA), reattachment rate of retinal detachment, and postoperative complication rate. The study results may help to evaluate the efficacy and safety of inverted internal limiting membrane insertion combined with air tamponade in the treatment of MHRD in high myopia, and also compare the efficacy of the new treatment with the conventional “vitrectomy plus internal limiting membrane peeling plus silicone oil tamponade” method. This trial may provide a novel surgical treatment for MHRD in high myopia with more effectiveness and less pain. ClinicalTrials.gov, NCT03383731 . Registered on 19 December 2017. Retrospectively registered.
机译:黄斑裂孔视网膜脱离(MHRD)最常见于高度近视,会导致严重的视力障碍,并大大降低生活质量。这项研究的目的是评估倒置内部限制膜联合空气填充塞治疗高度近视MHRD的疗效和安全性,并将其与常规“玻璃体切除术加内部限制膜剥离”的治疗效果进行比较。加硅油填塞”的方法用于高度近视相关的MHRD。在该临床试验中,将38位高度近视的MHRD患者随机分为两组(第1组:标准3口23口标准平玻璃体切除术+内膜剥离+空气交换+硅油输注;第2组:标准的3端口23口径扁平玻璃体切除术+内部限制膜剥离+倒置内部限制膜插入+流体交换)。主要结局是初次手术后3个月内的黄斑裂孔闭合率。次要结果是最佳矫正视力(BCVA),视网膜脱离的再附着率和术后并发症发生率。这项研究结果可能有助于评估倒置内部限制膜联合空气填充塞治疗高度近视MHRD的疗效和安全性,并将新疗法与常规“玻璃体切除术加内部限制膜剥脱加法”相比较。硅油填塞”法。该试验可以为高度近视的MHRD提供一种新颖的手术治疗方法,其疗效更高,痛苦更少。 ClinicalTrials.gov,NCT03383731。 2017年12月19日注册。追溯注册。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号